anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Acute appendicitis is the most common surgical emergency in Ethiopian clinical practice. Although a multitude of scoring systems have been used in clinical practice, none have been universally validated. The purpose of this study was to validate the Raja Isteri Pengiran Anak Saleha Appendicitis (RIPASA) scoring system in the Ethiopian context.
METHODS: A total of 315 consecutive patients who presented with a presumptive diagnosis of acute appendicitis and were planned to undergo appendectomy were studied. All the studied patients had diagnostic sonography and underwent the RIPASA scoring system. The sensitivity, specificity, positive predictive value, and negative predictive value of RIPASA and ultrasound results with intraoperative gross examinations.
RESULTS: The mean age of the participants was 27.4 ± 11.5 years, with a male-to-female ratio of 1.6:1. The concordance between ultrasound and RIPASA for the diagnosis of acute appendicitis was 93.6%. The sensitivity, specificity, positive predictive value, and negative predictive value of RIPASA were 96.2%, 30.8%, 93.9%, and 42.1%, respectively. Similarly, the sensitivity, specificity, positive predictive value, and negative predictive value of ultrasound were 95.3%, 27.8%, 95.6%, and 26.3%, respectively. White cell count and RIPASA scores were weakly correlated with intraoperative stages of acute appendicitis, r(313) = 0.18, p = 0.001, and r(313) = 0.129, p = 0.022, respectively. The rate of a negative appendectomy was 6%.
CONCLUSION: RIPASA and ultrasound had equivalent performance in the diagnosis of acute appendicitis. In both cases, the rate of negative appendectomy was low enough to validate RIPASA for clinical practice in low-income institutions where sonographic diagnosis by a conventionally trained radiologist is not available.
Valproic acid (VPA) is one of the most prescribed drugs for epilepsy. Extended use of VPA not only induces hepatotoxicity but also impairs the cognitive functions. Metformin has been reported to prevent epileptogenesis and enhance memory. To counter the VPA-induced adverse events, it is hypothesized that combination of sub-therapeutic dose of VPA with metformin may attenuate the toxicity stemming from the therapeutic dose of VPA. Pentylenetetrazole (PTZ)-induced kindling model of epilepsy in mice was used to assess the combined effects of sub-therapeutic dose of VPA (100 mg/kg) and metformin (200 mg/kg). The memory performance was analyzed by passive avoidance test, while alkaline comet assay was used to determine genotoxicity. Histopathological examination and serum biochemical analysis was performed to determine hepatotoxicity. Results showed that combination dose of VPA with metformin reduced seizure scores. VPA (300 mg/kg) administered as a single agent did not enhance memory impairment caused by PTZ, however, combination of sub-therapeutic dose of VPA with metformin enhanced memory function. Furthermore, in alkaline comet assay, combination therapy demonstrated reduced genotoxicity compared to the VPA 300 mg/kg. Histopathological examination of liver and analysis of serum hepatic enzymes revealed that combination therapy (VPA + metformin) reversed the toxicity as seen in case of PTZ or VPA (300 mg/kg) treated animals with no other treatment given. Based on the study data, it is concluded that the combination of sub-therapeutic dose of VPA with metformin might be used for epileptic seizures. This will prevent the hepatotoxicity and enhanced memory functions as compared to the VPA given as a single agent therapy.
Salbultamol inhalation solution for nebulization containing 2.5 mg in 2.5 mL aqueous solution. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
Lipopolysaccharides are obtained by cultivating Aerobacter aerogenes in an aqueous nutrient medium under submerged aerobic conditions until rapidly growing cells are obtained, and then removing the cells from the medium and recovering lipopolysaccharide from the isolated cells.  In an example Aerobacter aerogenes cells made from experimental tank lysine fermentations are mechanically agitated, dissolved in water rendered alkaline with KOH and then are incubated at 37 DEG  C. in a trypsin medium.  The medium is then centrifuged and the resulting solid is treated with 90% phenol and the aqueous layer separated and subsequently dialyzed through polythene.  The dialyzed aqueous medium is treated with aqueous sodium acetate and then absolute alcohol.  After centrifuging the sediment is withdrawn and after further purification a lipopolysaccharide fraction having an analysis of 3,25% nitrogen, 2,54% phosphorus and 17,8% glucose is obtained.  The lipopolysaccharides stimulate the reticuloendothelial phagocytic function and are useful as a prophylaxis against fatal doses of Staphylococous aureus and Pseudomonas fluorescens.  The lipopylsaccharides may be used in conjunction with corticosteroids (see Group VI).ALSO:Lipopolysaccharides obtained by cultivating Aerobacter aerogenes in an aqueous nutrient medium under submerged aerobic conditions until rapidly growing cells are obtained, and then removing the cells from the medium and recovering lipopolysaccharide from the isolated cells (see Group IV (a)) are used either alone or in admixture as a medicine for oral, intramuscular, subcataneous, intravenous or intraperitoneal administration.  The lipopolysaccharides stimulate the reticulo-endothelial phagocytic function and are useful as a prophylaxis against fatal doses of Staphylococcus auereus and Pseudomonas fluorescens.  The lipopolysaccharides may be used in conjunction with corticosteroids such as cortisone, hydrocortisone, 9a -fluorohydrocortisone, prednisone, prednisolone, 6-a -methylprednisone, 6-a -methylprednisolone, 9-a -fluoro-16-a -hydroxy-hydrocortisone, 9 - a - fluoro - 16 - a  - methylhydrocortisone, 9 - fluoro - 16 - b  - methylhydrocortisone ACTH or a 21-lower acyl ester thereof.  In specific examples from 0.005 to 0.01% of the lipopolysaccharide is mixed with a corticosteroid and conventional pharmaceutical adjuvants.  Other substances which may be added include penicillin, streptomycin, tetracycline, oxytetracycline, chlorotetracycline, oleandomycin and tri-acetyloleandomycin.
Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 5 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to initiation of androgen deprivation (week 0), again prior to initiation of radiotherapy (week 8), at the end of radiation therapy (week 16) and at 6 months and 12 months after the conclusion of radiation therapy.
Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
PURPOSE: Currently, precise patient body weight (BW) at the time of diagnostic imaging cannot always be used for radiation dose management. Various methods have been explored to address this issue, including the application of deep learning to medical imaging and BW estimation using scan parameters. This study develops and evaluates machine learning-based BW prediction models using 11 features related to radiation dose obtained from computed tomography (CT) scans.
METHODS: A dataset was obtained from 3996 patients who underwent positron emission tomography CT scans, and training and test sets were established. Dose metrics and descriptive data were automatically calculated from the CT images or obtained from Digital Imaging and Communications in Medicine metadata. Seven machine-learning models and three simple regression models were employed to predict BW using features such as effective diameter (ED), water equivalent diameter (WED), and mean milliampere-seconds. The mean absolute error (MAE) and correlation coefficient between the estimated BW and the actual BW obtained from each BW prediction model were calculated.
RESULTS: Our results found that the highest accuracy was obtained using a light gradient-boosting machine model, which had an MAE of 1.99 kg and a strong positive correlation between estimated and actual BW (ρ = 0.972). The model demonstrated significant predictive power, with 73% of patients falling within a ±5% error range. WED emerged as the most relevant dose metric for BW estimation, followed by ED and sex.
CONCLUSIONS: The proposed machine-learning approach is superior to existing methods, with high accuracy and applicability to radiation dose management. The model's reliance on universal dose metrics that are accessible through radiation dose management software enhances its practicality. In conclusion, this study presents a robust approach for BW estimation based on CT imaging that can potentially improve radiation dose management practices in clinical settings.
SSRIs and SNRIs, including fluvoxamine maleate tablets, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Based on data from the published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Use in Specific Populations (8.1)]. Bleeding events related to SSRIs and SNRIs have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages.

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of fluvoxamine maleate tablets and NSAIDs, aspirin, or other drugs that affect coagulation [see Warnings and Precautions (5.8)].
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: group of inventions refers to medicine and is applicable in the form of liposome-containing compounds for cancer therapy. A liposome contains one or more phosphatidylcholines, a first derivative of N-(ë)-dicarboxylic acid and phosphatidylethanolamine, an orientation modified derivative of N-(ë)-dicarboxylic acid and phosphatidylethanolamine, an encapsulated therapeutic agent and at least one additional lipid which represents cholesterol or a cholesterol derivative. The orientation modified derivative of N-(ë)-dicarboxylic acid and phosphatidylethanolamine contains an orientation ligand attached to a second derivative of N-(ë)-dicarboxylic acid and phosphatidylethanolamine. The first derivative of N-(ë)-dicarboxylic acid and phosphatidylethanolamine is presented by formula 1, ^ ^ and the second derivative of N-(ë)-dicarboxylic acid and phosphatidylethanolamine is presented by formula 3, . The orientation ligand preferentially represents transferring, while the encapsulated therapeutic agent is oxalyplatine. The liposome is free from non-modified phosphatidylethanolamine, egg phosphatidylcholine or hydrophilic polymer used to prolong a half lifetime of the liposome in a circulatory channel, and the orientation ligand is other than an intact antibody. What is also described is a method of producing the liposome and a method of treating cancer with using it. ^ EFFECT: group of inventions provides better target delivery of the therapeutic substance in the tumour cells. ^ 113 cl, 25 dwg, 4 tbl, 30 ex
A system and related method for remotely monitoring the health of a patient are provided to inform the patient as to his/her state of health. Data on a patient physiological parameter is analyzed at a patient site using Shewhart's rules of detection. The patient is notified when the conditions for one of Shewhart's rules are met, which may indicate a significant change in the patient's health status. Preferably, the notice to the patient is tailored by the patient's health care provider, and may instruct the patient to contact the health care provider or take some other preventative action. Preferably, information is transferred from the patient site to a health care provider site. An elementary system has a patient operated sensor for taking physiological measurements and converting them into an indexed data record, a patient site data processing unit with a database for storing such indexed data records, and a SPC instruction set which enables the patient site data processing unit to perform a SPC analysis on the indexed data records to determine if Shewhart's rules are met. Means for notifying the patient that one of Shewhart's rules is met are also provided.
In an approach to adjusting notification alerts based on biometric data, one or more computer processors receive one or more user preferences from a first user. One or more computer processors receive a prompt from a computing device to generate a notification. One or more computer processors retrieve biometric data associated with the first user. One or more computer processors determine a biometric state of the first user based on the retrieved biometric data. One or more computer processors adjust a notification alert based on the received one or more user preferences and on the determined biometric state of the first user. One or more computer processors generate the notification alert.
PROBLEM TO BE SOLVED: To obtain a shampoo having a dandruff germ-protecting effect, blood circulation improving effect and antipruritic effect on the scalp, and a hair growing effect. SOLUTION: This shampoo contains one or more kinds of plant extracts of Orchidaceae plants belonging to the Calanthe or the Phaius as active components. For collecting the plant extract, for example, Calanthe discolor Lindl. or Phaius flavus Lindl. is washed with water and cut into fine pieces, 300 g of the fine pieces are immersed in 1000 cc of a 25%-alcohol aqueous solution to perform extraction and filtered. When the shampoo prepared by compounding the plant extract in an amount of 20 wt.% is applied for 3 months, dandruff germ-protecting effect, blood circulation improving effect and antipruritic effect on the scalp, and hair growing effect are observed.
Circulating biomarkers have been proposed for early identification of aortic dilatation progression associated with bicuspid aortic valve (BAV), but matrix metalloproteinases (MMPs) are distinguished as signatures of increased extracellular matrix degradation, a landmark of aneurysm formation. The current study aims to identify the role of MMP-1, MMP-2, MMP-9, and the MMP inhibitor, TIMP-1, in identifying aortic dilation in children with BAV. We conducted a study on 73 children divided into two study groups, depending on the presence of aortic dilatation (group 1-43 BAV controls and group 2-30 children with BAV and aortic dilatation). Each patient underwent a cardiac ultrasound and, in each case, serum MMP-1, MMP-2, MMP-9, and TIMP-1 were quantified using xMAP technology. Comparison of the MMPs between the two study groups revealed significantly higher values only in the case of TIMP-1, among BAV controls. Moreover, the same TIMP-1 inversely correlated with aortic annulus absolute size and z score, as well as with ascending aorta z score. No particular correlation between the aortic phenotype and the presence of aortic dilatation was found. Future longitudinal research starting at pediatric ages could show the significance of MMPs screening in BAV individuals as predictors of aortic aneurysm formation.
Venous thromboembolism (VTE) is a disabling and potentially fatal outcome that may be acquired after having a stroke. The standard treatment to prevent the development of VTE is to give anticoagulation medication. However, this is not recommended in the UK after stroke. Instead the recommended treatment is Intermittent Pneumatic Compression (IPC), where cuffs placed around the lower legs are filled with air to help squeeze the legs and induce blood flow. However, not all patients are able to receive or tolerate IPC treatment. Another treatment which has shown promising results to prevent VTE in immobile patients after stroke, is with a medical device called the geko™ device. The geko™ device is a CE marked medical device which means the manufacturer has checked that the device complies with the essential safety and performance requirements for its' intended use which is to increase blood circulation to help prevent VTE. The aim of this study is to determine if the geko™ device is more effective at preventing VTE in immobile acute stroke patients, than the current IPC standard of care treatment. Following the consent process, stroke patients will be randomised to receive either IPC or geko device. Both devices will be applied until the patient can walk again without help, or for a maximum of 30 days. A compression Doppler exam of the legs will be conducted after 7 days or at discharge if the patient recovers earlier (optional) and after 14 days (mandatory). At 14 days post-randomisation, a patient questionnaire about the comfort of the device, as well as additional health information will be collected. At 30 days after randomisation, additional information about symptomatic DVTs or PEs etc., will be collected from the participant's medical notes. A final follow-up will then be conducted over the phone after 90 days to find out about the patient's recovery, health, mobility and quality of life.
In the prodn. of human fostal cell cultures, (a) virus free human 3-6 month foetal material is cut into small pieces and washed with Hanks soln. pH 7.2; (b) the comminuted material is incubated with 25% trypsin soln. (changed every 15-30 mins.) at 37 degrees C and pH 7.5 for 20-30 mins.; (c) suspended cells are syphoned off and this procedure repeated until all cells are in suspension; (d) the resulting cells are incubated ca 2 days at 37 degrees C without agitation and dead cells are removed; (e) the cultures are incubated 3-4 days without agitation, the nutrient medium being changed every 2-4 days; (f) optionally, cells are separated from the glass walls by incubating 15-30 mins. with 0.2% trypsin soln. at 37 degrees C, and then subjected to a second incubation as in step (e); (g) when only 30% of the cells are still mitotic, the culture is centrifuged; and (h) the resulting cells are suspended in 15% glycerine-contg. phosphate buffer at a concn. of ca 2000 cells/3 mm3. Administration i.v. or i.m. in the treatment of heart disease, kidney disease, liver disease, chronic degenerative disease, circulatory disorders, genital disease and nervous disorders, and to counteract the effects of ageing. The foetal cells used must be in an indifferent state. They can be used instead of fresh animal cells in the cell therapy method of Niehans.
Normal tension glaucoma is one of the most common cause of primary open angle glaucoma in Korea. Even though, we still do not know what the cause is. Only IOP-lowering drugs are the currently available therapeutic method. Glutathione is one of the mostly high concentrated intracellular antioxidants. We find apoptosis of neuronal cell in the mouse retina by systemic depletion of glutathione using buthionine sulfoximine. Glutathione is also known to be reduced in primary open angle glaucoma with high IOP. So we are planning to evaluate systemic glutathione level in normal tension glaucoma.

Blood samples will be obtained by venipuncture to the antecubital vein of normal tension glaucoma patients and age-matched normal controls. Five milliliters of blood will be collected in EDTA-treated tubes (to prevent oxidation). Thirty microliters of blood will be then transferred into centrifuge tubes, and will be added 33.3 microliter of 5-sulfosalicylic acid (SSA), 100mg/mL within 10 minutes from the blood collection.Each sample will be then diluted with 936.7 microliter sodium phosphate buffer (pH 7.5), and the content of each tube will be mixed rapidly in a centrifuge at 13,000 rpm for 5 minutes. A portion of supernatant (150 microliter) will be then collected into clean centrifuge tubes and immediately cooled at -70°C. To each well of a 96-well plate, 150 microliter of daily buffer (3 mg NADPH into 10 mL sodium phosphate buffer), 50microliter of DTNB solution, and 25 microliter of standards or samples will be added in quadruplicate, and the plate will be incubated at 37 °C for 3 minutes.Finally, 25 microliter GSSGR will be added to the previous mixture, and the plate will be read at 410 nm using a 96-well plate reader(UV spectrophotometer).
To provide zonisamide drug substance particles capable of improving elution properties.SOLUTION: There is provided drug substance particles formed of zonisamide or a salt thereof and having an adjusted cumulative 50% particle size (D50) of 18 μm or less on a volume basis. The drug substance particles may have a cumulative 10% particle size (D10) of less than 3.6 μm on a volume basis and may have a cumulative 90% particle size (D90) of 15 μm or more on a volume basis. Granules comprising the drug substance particles may be prepared. The granules may be solid. Preferably, the granules may be substantially free of cellulose ether having a hydroxy C2-4 alkyl group. Orally disintegrating tablets comprising the granules and rapidly disintegrating particles may be prepared. The rapidly disintegrating particles may contain ethyl cellulose. The rapidly disintegrating particles may further contain sugar alcohols, carmellose, silicic acids, and crospovidone. Preferably, the orally disintegrating tablet may be substantially free of crystalline cellulose. Preferably, the orally disintegrating tablet is substantially free of cellulose ethers and starches having a hydroxy C2-4 alkyl group.SELECTED DRAWING: None
The invention discloses toothpaste containing carbon coating particles, and belongs to the technical field of daily chemicals. The product disclosed by the invention contains the carbon coating particles, abrasive, adhesive, surfactant, humectant, flavoring agent, water and the like, and is manufactured by adopting the conventional toothpaste production process. Compared with the conventional toothpaste, the toothpaste containing the carbon coating particles has the effects of absorbing bad breath and stains, and enhancing fresh breath and oral hygiene function. Carbon powder is subjected to saturation adsorption easily during the medium and long term storage in pasty fluid, and loses the re-adsorption capability, therefore, the carbon powder material is enabled to be isolated from other ingredients of the pasty fluid, and the activity of the carbon powder material can be kept. The carbon coating particles contain outer layer coating materials, such as carbon core materials, microcrystalline cellulose, cane sugar, starch and modified cellulose. Different pigments can be added, so that the particles are endowed with different colors. Different carbon powder materials, such as activated carbon with different particle diameters, bamboo charcoal, which have the absorption function, can be selected as the carbon core materials.
PURPOSE: A chitosan micro-flake, which promotes surprisingly its own capability of overlaying the skin, is provided. The chitosan micro-flake has functions such as antibiosis, hemostatic activity, bioavailability, piling up a cell and anti-odor and can be used as clinical overlay and raw materials for cosmetics. Also, a preparation method thereof is provided. CONSTITUTION: A chitosan micro flakes are prepared by dissolving chitosan in a weak acid solvent such as organic acid, inorganic acid, inorganic salt and organic solvent in a special ratio then freeze-drying them; extracting them to obtain porous chitosan film with a high degree of purity; and shattering them to pieces. Preferentially, the chitosan has a degree of polymerization of 20 -10,000 and a degree of acetylation of 60-90 %. The chitosan micro flakes have a panel structure of 0.1-10 micrometer in a thickness and 2-2,000 micrometer in a width.